Key takeaways

  • Colchicine, NSAIDs and corticosteroids treat flare inflammation and pain. Allopurinol and febuxostat lower urate over time; they are not immediate painkillers. NUH
  • A urate blood test can be normal or low during an acute flare, according to Singapore ACE. Colchicine and NSAIDs do not remove the long-term urate burden, and established urate-lowering treatment normally continues during a flare. ACE
  • Kidney function, interactions and severe skin-reaction risk need a clinical plan. ACE estimates severe skin reactions in around 3 of every 1,000 allopurinol users and advises monitoring everyone starting treatment. ACE

Gout flare medicine versus uric-acid-lowering medicine

Gout Flare Medicine vs Uric-Acid-Lowering Medicine

Colchicine, NSAIDs or corticosteroids may control an acute flare, while allopurinol or febuxostat lower urate over time for selected patients. A medicine for one role should not be judged by whether it performs the other.

What treats an acute gout flare?

Colchicine, an NSAID or a corticosteroid may treat the inflammation. Singapore ACE says to begin flare treatment as soon as possible, rest the joint and apply ice packs. NUH lists naproxen, diclofenac, indomethacin, etoricoxib and celecoxib as NSAID examples. Steroid options include oral prednisolone or an injection into a muscle or the affected joint. ACE, NUH The suitable option depends on how early the flare is treated, severity, kidney and liver function, ulcer and bleeding risk, cardiovascular disease, diabetes, infection concerns and interacting medicines.

These are not interchangeable “gout tablets.” Colchicine has a narrow margin between useful and harmful exposure and important interaction risks. NSAIDs have kidney, stomach, bleeding and heart considerations. Corticosteroids affect glucose, infection risk and other conditions. A previous flare prescription should not be automatically repeated if health or medicines have changed.

NUH describes joint aspiration: fluid is drawn through a needle from the swollen joint, then checked under a microscope for gout crystals. X-rays may show joint destruction; ultrasound or dual-energy CT is used in selected cases. A high uric-acid result without joint inflammation does not itself diagnose gout. NUH A hot, swollen joint can also be septic arthritis, which requires urgent treatment. Fever, marked illness, a first severe attack or an unusual joint pattern should not be assumed to be gout from an online photo.

What does urate-lowering therapy do?

Urate-lowering therapy reduces serum urate so crystals stop accumulating and gradually dissolve. It is a long-term strategy for people who meet treatment criteria, not a way to numb a painful joint on demand.

Allopurinol and febuxostat reduce uric-acid production through xanthine-oxidase inhibition. They are not direct substitutes in every user. Kidney function, cardiovascular history, prior reactions, other medicines and the clinician’s target and monitoring plan can affect selection.

ACE lists treatment criteria including at least two flares a year, any tophus, gout damage visible on imaging or a history of urinary stones. It recommends starting low and increasing gradually under clinical supervision, using blood tests and the clinical response. NUH gives a urate target below 360 micromol/L, or below 300 micromol/L with tophi. These are blood-test goals, not medicine amounts. ACE, NUH

Why can flares occur around a treatment change?

Changing urate levels can mobilise existing crystals and trigger early flares. That is why the clinician may prescribe temporary anti-inflammatory prevention alongside urate-lowering treatment. ACE recommends colchicine prophylaxis generally for up to 6 months, adjusted for flare occurrence; other options may be considered if unsuitable. HealthHub describes colchicine or an NSAID alongside febuxostat during its first 6 months. An early flare does not mean the long-term medicine has failed as a painkiller. ACE, HealthHub

Do not stop established urate-lowering treatment during a flare unless the treating clinician gives a different instruction or a serious adverse reaction is suspected. Abrupt, repeated starting and stopping can destabilise the long-term plan. Ask what to continue and which separate medicine handles the flare.

Mark the prescription list with flare medicine and urate-lowering medicine. Ask the pharmacist to explain any apparent overlap. Colchicine itself can be prescribed for a current flare or for prevention during early urate-lowering treatment; the instructions differ. ACE also flags interactions with macrolide antibiotics, azole antifungals, statins, verapamil and diltiazem, with greater toxicity risk in kidney or liver impairment. ACE

Why do rash and ancestry enter the allopurinol discussion?

HLA-B*58:01 is associated with a substantially increased risk of severe skin reactions to allopurinol. The variant’s prevalence differs across ancestry groups, including several Asian populations. Kidney impairment and older age also increase risk. ACE recommends counselling and monitoring for everyone starting allopurinol or febuxostat, and notes that abnormalities in full blood count, alanine aminotransferase or aspartate transaminase may indicate a severe reaction. ACE

ACE names Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS (drug reaction with eosinophilia and systemic symptoms). Most occur in the first weeks or months. Its estimate for allopurinol is around 3 cases per 1,000 users. Reactions can occur without HLA-B*58:01, and a positive test does not predict one with certainty: ACE estimates about 2% of carriers starting allopurinol may develop a severe reaction. ACE

Routine genotyping of everyone with gout is not recommended in that Singapore guideline. Testing may be considered before allopurinol for people already at higher risk through kidney impairment or older age, taking costs into account. The prescriber considers ancestry, kidney function, starting strategy and local guidance. Ethnicity alone is neither a diagnosis nor a reason to arrange testing independently.

Contact the clinician promptly about any new rash on allopurinol or febuxostat. For allopurinol, NUH says to stop the medicine and consult a doctor if new rashes or oral ulcers appear. Get emergency assessment for blistering, mouth sores, facial swelling, fever, eye involvement or widespread peeling. A suspected severe reaction must not be tested by taking the medicine again. NUH

What changes the answer?

The treatment role, diagnosis, organ function, interacting medicines and previous reactions determine the plan.

  • Is it an acute flare or long-term prevention question? The roles and time horizons differ.
  • Certainty of diagnosis. Infection and other crystal or inflammatory diseases can mimic gout.
  • Kidney and liver function. These influence several flare and urate-lowering options.
  • Ulcer, bleeding and cardiovascular risk. These can change NSAID and urate-lowering decisions.
  • Interactions. Colchicine, allopurinol and febuxostat each have important medicine-specific conflicts.
  • Severe-reaction risk. Ancestry, HLA-B*58:01, kidney function and prior rash belong in the prescriber’s assessment.

Seek urgent help for a hot swollen joint with fever or severe illness, inability to bear weight when the diagnosis is uncertain, or a severe drug reaction. Bring the flare diary, urate results and medicine packs to routine review. ACE notes that urate may be normal or low during a flare; record when the sample was taken. The gout condition page and pain-management catalogue provide background for the clinical plan. ACE

Sources